HTLV, a multi organ oncovirus.

Area of Science:

• Virology
• Immunology
• Infectious Diseases

Background:

• Human T lymphotropic virus type 1 (HTLV-I) is a retrovirus linked to severe conditions such as HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) and Adult T cell Leukemia-Lymphoma (ATLL).
• HTLV-I infection affects a small fraction (3-5%) of carriers but is also associated with a broader spectrum of conditions including arthropathy, lymphomas, and autoimmune disorders.
• Research has explored factors influencing disease development and progression in HTLV-I carriers, identifying numerous non-associated disease categories.

Purpose of the Study:

• To systematically review and classify the diverse range of diseases associated with HTLV-I infection.
• To categorize HTLV-I related disorders into distinct manifestations: related, accelerated, and associated diseases.
• To highlight the complex and often unclear interaction between HTLV-I and the host immune response.

Main Methods:

• Literature review and analysis of studies investigating HTLV-I and its associated health conditions.
• Categorization of identified diseases based on their relationship to HTLV-I infection (related, accelerated, associated, non-associated).
• Examination of the host immune response in the context of HTLV-I infection, noting inflammatory and anti-inflammatory observations.

Main Results:

• HTLV-I related disorders were classified into three primary categories: related, accelerated, and associated diseases.
• Thirteen categories of non-associated diseases were identified, encompassing conditions like reproductive disorders, cardiovascular disease, and various organ-specific diseases.
• The interplay between HTLV-I and the host immune system was found to be complex, with evidence of both inflammatory and anti-inflammatory immune responses.

Conclusions:

• A clear classification of HTLV-I disorders into related, accelerated, and associated categories provides a framework for understanding disease manifestations.
• The complex immune response to HTLV-I necessitates further systematic research to elucidate disease pathogenesis.
• Establishing a global network is crucial for controlling and preventing HTLV-I affiliated diseases.